PUBLISHER: DelveInsight | PRODUCT CODE: 1705108
PUBLISHER: DelveInsight | PRODUCT CODE: 1705108
Alzheimer's Disease - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights:
- In 2023, the 7MM reported approximately 15,840 thousand diagnosed prevalent cases of Alzheimer's disease, reflecting a significant disease burden. This high prevalence underscores the need for innovative treatments to address the rising impact on healthcare systems and patient care.
- In 2023, among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of Alzheimer's disease, representing 30% of the total cases, followed by France (24%). Analysis by DelveInsight's experts indicates that the overall diagnosed prevalent cases of Alzheimer's disease are expected to rise in the coming years.
- According to DelveInsight analysis, nearly 2,325 thousand males and 4,650 thousand females were affected with Alzheimer's disease in the US in 2023. DelveInsight estimates that these numbers will increase by 2034.
- DelveInsight's epidemiological model estimates that in 2023, the 75-84 age group in the EU4 and the UK had the highest Alzheimer's disease cases, totaling 2,300 thousand. In contrast, the under 65 age group had the fewest cases, with nearly 125 thousand recorded.
- DelveInsight's estimates indicate that in 2023, Japan had approximately 2,470 thousand diagnosed prevalent cases of agitation associated with Alzheimer's disease, a figure expected to grow by 2034. This behavioral symptom, marked by restlessness, irritability, aggression, and anxiety, significantly diminishes patient quality of life and heightens caregiver strain.
- The current market of Alzheimer's disease includes approved therapies such as LEQEMBI (lecanemab), along with off-label therapies like galantamine, memantine, and others, contributing to a market size of USD 3,610 million in the 7MM in 2023. The market size is expected to increase with the projected launch of emerging therapies during the forecast period (2024-2034).
- In 2023, the market size of Alzheimer's Disease was highest in the US among the 7MM, accounting for approximately USD 1,940 million which is further expected to increase by 2034.
- In September 2024, Japan's Ministry of Health, Labour, and Welfare approved KISUNLA (donanemab-azbt, 350 mg/20 mL) for intravenous infusion every four weeks. Developed by Eli Lilly, the drug targets adults with early symptomatic Alzheimer's disease, including mild dementia, both with confirmed amyloid pathology.
DelveInsight's "Alzheimer's Disease - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Alzheimer's disease, historical and forecasted epidemiology as well as the Alzheimer's disease market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
The Alzheimer's Disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Alzheimer's disease market size from 2020 to 2034. The Report also covers current Alzheimer's disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Geography Covered:
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2020-2034
Disease Understanding and Treatment Algorithm
Alzheimer's Disease Overview
Alzheimer's disease is a progressive, irreversible neurological disorder, primarily impacting memory, reasoning, and cognitive abilities. It is the leading cause of dementia, responsible for roughly 60-80% of all cases. Though often emerging in the mid-60s, early-onset Alzheimer's can affect individuals as young as their 40s or 50s, albeit rarely. Initial symptoms commonly include memory loss that significantly interferes with daily life, followed by confusion, language difficulties, impaired judgment, and behavioral changes. The disease's exact cause remains unknown, but it is associated with abnormal accumulations of Amyloid Beta protein plaques and tau protein tangles in the brain, which disrupt cellular communication and lead to cell death. Increasing age and family history are recognized as key risk factors for Alzheimer's disease.
Alzheimer's Disease Diagnosis
Diagnosing Alzheimer's disease remains challenging due to its gradual onset and overlapping symptoms with other cognitive disorders. The diagnosis primarily relies on clinical assessments, including a detailed medical history, cognitive tests, and evaluations of memory, reasoning, and language skills. Neuroimaging techniques, like MRI and PET scans, help detect structural brain changes, while biomarkers in cerebrospinal fluid can reveal amyloid and tau protein abnormalities. However, definitive diagnosis often occurs post-mortem through brain tissue examination.
The complexity of Alzheimer's disease diagnosis is compounded by variability in symptom progression and the absence of a single diagnostic test. Additionally, the need for specialized tools and resources makes early diagnosis difficult, especially in low-resource settings. Misdiagnosis risks are high, which can delay appropriate interventions and add stress for patients and caregivers. Improved diagnostic accuracy through advancements in biomarker research and neuroimaging is critical to enabling timely, targeted treatments and addressing these diagnostic challenges in Alzheimer's disease.
Alzheimer's Disease Treatment
The treatment landscape for Alzheimer's disease centers around managing symptoms rather than halting disease progression. Current FDA-approved treatments, including cholinesterase inhibitors and the NMDA receptor antagonist memantine, temporarily aid cognitive functions but do not reverse the underlying pathology. Recently, anti-amyloid monoclonal antibodies, like aducanumab, have targeted amyloid plaques to potentially slow cognitive decline, though these options have faced scrutiny regarding efficacy and safety. Additionally, non-pharmacological interventions-such as cognitive therapy, physical exercise, and lifestyle modifications-are vital components of patient care to support mental and physical health.
However, treatment challenges persist. The progressive nature of Alzheimer's disease, coupled with an incomplete understanding of its causes, limits therapeutic advancements. Effective treatment is further hindered by high costs, potential adverse effects, and the variability of patient responses. Consequently, addressing these challenges requires ongoing research to develop therapies that effectively target Alzheimer's disease's complex pathology and enhance patients' quality of life.
Alzheimer's Disease Epidemiology
As the market is derived using a patient-based model, the Alzheimer's disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of Alzheimer's Disease, Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease, Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease, Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease, Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease, and Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
- In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Alzheimer's disease in Japan were nearly 3,920 thousand in 2023.
- In 2023, the United States represented approximately 44% of diagnosed Alzheimer's disease cases across the 7MM, with 6,980 thousand cases, a figure anticipated to increase by 2034, as per DelveInsight's estimates.
- In Japan, there were nearly 1,390 thousand diagnosed males and 2,530 thousand cases of females with Alzheimer's disease in 2023, highlighting gender distribution among the population.
- Age-specific cases in the US are categorized into four groups: under 65, 65-74, 75-84, and 85+ years. In 2023, the 75-84 age group held the highest prevalence with nearly 2,790 thousand cases, whereas the under-65 group recorded the lowest with nearly 175 thousand cases.
- Alzheimer's disease is also classified by severity: mild cognitive impairment (MCI), mild, moderate, and severe dementia. Within EU4 and the UK, the MCI stage had the highest prevalence with around 2,560 thousand cases in 2023, while severe dementia showed the lowest with 645 thousand cases.
- The US reported nearly 5,233 thousand diagnosed cases of agitation associated with Alzheimer's disease in 2023, which is expected to grow by 2034.
- In Japan, approximately 2030 thousand cases of psychosis in Alzheimer's disease were documented in 2023, a number forecasted to increase over time.
Alzheimer's Disease Drug Chapters
The drug chapter segment of the Alzheimer's disease report encloses a detailed analysis of Alzheimer's disease off-label drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Alzheimer's disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Marketed Drugs
LEQEMBI (lecanemab): Biogen Inc./Eisai Co., Ltd.
LEQEMBI, an FDA-approved treatment for Alzheimer's, specifically targets patients in the Alzheimer's disease or mild dementia stages. Developed as a humanized IgG1 monoclonal antibody, LEQEMBI addresses amyloid B (AB) pathology by reducing both soluble and insoluble forms of AB to slow disease progression.
With ongoing prescription expansion, the focus includes customized facility information on the drug, reimbursement support, and system efficiency enhancements. Approved by regulatory bodies in Great Britain (August 2024) and Japan (September 2023), LEQEMBI marks a significant milestone as the first approved therapy in Europe to target an Alzheimer's-related pathology directly.
In May 2023, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted lecanemab designation under the Innovative Licensing and Access Pathway (ILAP). The MHRA, which oversees the regulation of medicines and medical devices in the UK, recognized lecanemab for this accelerated pathway to enhance patient access.
KISUNLA (Donanemab): Eli Lilly and Company
KISUNLA (donanemab-azbt), developed by Eli Lilly, targets amyloid plaques in patients with Alzheimer's disease or early symptomatic Alzheimer's disease confirmed by amyloid pathology. This humanized IgG1 monoclonal antibody addresses amyloid B accumulation-a key contributor to Alzheimer's by focusing on insoluble N-truncated pyroglutamate amyloid beta plaques.
Administered intravenously every four weeks, KISUNLA's structured dosing regimen was informed by Phase III TRAILBLAZER-ALZ 2 trial data, supporting approvals in the US (July 2024) and Japan (September 2024). Unique to KISUNLA is the potential to halt treatment once plaques clear, which may optimize efficacy and lower treatment costs.
In June 2021, Eli Lilly's donanemab received the US FDA's breakthrough therapy designation (BTD) for treating Alzheimer's disease
Emerging Drugs
Masitinib (AB1010): AB Science
Masitinib, an orally administered tyrosine kinase inhibitor, targets neuro-immune cells such as mast cells and microglia that accumulate in the Central Nervous System (CNS) at effective concentrations. Evidence increasingly links these cells to Alzheimer's disease pathology. In preclinical studies, masitinib demonstrated synaptic protection by inhibiting mast cells, which contributed to improved spatial learning and recovery of synaptic markers in Alzheimer's disease models. The drug is currently in Phase III clinical trial and development for the disease.
Clinically, masitinib showed promise in treating mild to moderate Alzheimer's disease, with a Phase II trial confirming potential benefits. Additionally, a Phase IIb/III study found that masitinib significantly slowed cognitive decline. A confirmatory Phase III trial is currently underway.
Valiltramiprosate (ALZ-801): Alzheon, Inc.
ALZ-801 is an oral small-molecule prodrug that effectively blocks the formation of neurotoxic amyloid oligomers in the brain. Structurally, it is a valine-conjugated version of tramiprosate, metabolizing into homotaurine in the body, which enhances absorption and extends blood retention compared to tramiprosate. Both ALZ-801 and tramiprosate are metabolized to 3-sulfopropanoic acid (3-SPA), a natural brain compound that prevents AB42 aggregation.
ALZ-801 was specifically designed to improve tramiprosate's gastrointestinal tolerance and pharmacokinetics, allowing for efficient gut absorption and conversion to active tramiprosate in the bloodstream. Phase I studies indicate improved gastrointestinal tolerance and stable plasma levels.
Currently in Phase III, ALZ-801 is being evaluated as a potential disease-modifying treatment for early-stage Alzheimer's disease.
Tricaprilin (CER-0001): Cerecin
Cerecin's tricaprilin (CER-0001) (also known as AC-1204) is an innovative oral formulation of caprylic triglyceride, designed to induce a mild state of chronic ketosis that enhances mitochondrial metabolism. Early in the progression of Alzheimer's disease, there is a notable decline in cerebral glucose utilization. Tricaprilin aims to counteract this by providing an alternative energy source for cells, thus boosting metabolic activity in Alzheimer's disease. Caprylic acid is converted into ketone bodies, including acetoacetic acid and B-hydroxybutyric acid, which can then be transformed into acetyl-CoA, facilitating energy production through the citric acid cycle.
Clinical studies indicate that CER-0001 is a promising ketogenic agent that demonstrates cognitive improvement in subjects with mild to moderate Alzheimer's disease, particularly among those who are APOE4-negative.
Bezisterim (NE3107): BioVie
NE3107 is an oral small molecule designed to effectively penetrate the blood-brain barrier, serving as both an anti-inflammatory agent and an insulin sensitizer. It selectively targets Extracellular Signal-regulated Kinase (ERK) to inhibit inflammatory pathways by blocking ERK/NF?B activation and decreasing tumor necrosis factor (TNF) production, particularly in response to inflammatory stimuli such as lipopolysaccharides. This mechanism holds promise for reducing pathological inflammatory signaling in peripheral tissues and the Central Nervous System (CNS), potentially alleviating insulin resistance, diminishing inflammatory cell infiltration in the CNS, and modulating microglial activation without impairing their critical functions.
NE3107's dual action may disrupt this detrimental cycle, presenting a novel therapeutic strategy for Alzheimer's disease. Previously known as HE3286, NE3107 is a synthetic analog of the adrenal hormone dehydroepiandrosterone (DHEA) metabolite and is also being explored for treating conditions such as Parkinson's disease, multiple myeloma, and prostate cancer. BioVie has completed Phase III trials for NE3107 as a treatment for mild to moderate Alzheimer's disease.
In March 2024, BioVie showcased findings at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2024) held in Lisbon, Portugal. The data presented from a Phase III trial of NE3107 in patients with mild to moderate Alzheimer's disease suggest its potential to realign physiological processes, which may lead to a reduction in neurocognitive decline associated with aging.
Alzheimer's Disease Market Outlook
Currently, available therapies for Alzheimer's disease primarily target symptom management by modulating key neurotransmitters, including acetylcholine, serotonin, and noradrenaline, while aiming to reduce the activity of glutamate and dopamine. However, these approaches often lead to potential side effects, highlighting the necessity for personalized treatment strategies that consider patient comorbidities and potential drug interactions. Recent approvals, such as LEQEMBI (lecanemab) by Biogen and Eisai, Eli Lilly's KISUNLA (donanemab-azbt), and Brexpiprazole (REXULTI), signify a shift toward more tailored therapeutic options.
Pharmacological treatments, including acetylcholinesterase inhibitors (AChEIs) and the NMDA receptor antagonist memantine, have been in use in the U.S. for over a decade. The US FDA and EMA have approved three AChEIs donepezil, rivastigmine, and galantamine Administered in over 60 countries for various stages of Alzheimer's disease. Despite demonstrating modest symptomatic benefits in clinical trials, the effectiveness of these therapies is temporary, necessitating regular re-evaluation.
Additionally, the benefit-risk ratio of these medications remains a topic of debate, influencing reimbursement decisions in some countries, such as France. Memantine, effective as monotherapy or in combination with AChEIs, serves to slow symptom progression in moderate to severe cases, further diversifying treatment options available for this challenging condition.
With a growing focus on advanced treatment options, the market for Alzheimer's disease is expanding, highlighting opportunities for innovation and investment in new therapies and technologies.
The Alzheimer's disease market has a rich pipeline and is poised for transformation with the anticipated introduction of therapies like Masitinib, Valiltramiprosate/ ALZ-801, Tricaprilin (CER0001), Bezisterim (NE3107) and others. The approval of these therapies could significantly impact market dynamics, although their success rates remain uncertain.
- The market size of Alzheimer's disease in the 7MM was ~USD 3,610 million in 2023, which is further anticipated to increase during the forecast period.
- The United States accounted for the highest market size of Alzheimer's disease approximately 54% of the total market size in 7MM in 2023, in comparison to the other major markets i.e., EU4 countries (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
- Among the EU countries, Germany had the highest market size with USD 267 million in 2023, while the UK had the lowest market size for Alzheimer's disease with USD ~104 million in 2023.
- The market size for Alzheimer's disease in Japan was estimated to be about USD 845 million in 2023.
- With the expected launch of upcoming therapies, such as Masitinib, Valiltramiprosate/ ALZ-801, Tricaprilin (CER0001), Bezisterim (NE3107) among others, the total market size of Alzheimer's disease is expected to show change in the upcoming years.
Alzheimer's Disease Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, Masitinib in the US is expected to be launched by 2027 with a peak share of 1.20%. Bezisterim is anticipated to take 7 years to peak with a slow medium uptake.
Alzheimer's Disease Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Alzheimer's disease emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Alzheimer's disease evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Washington University School of Medicine, St. Louis, US; University of Nevada, US; Hannover Medical School, Germany; Universite Paris Saclay, France; Universita di Palermo, Italy; Hospital Virgen De La Salud, Spain; University College London, the UK; and Kyoto University, Japan.
Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Alzheimer's disease market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report:
- The report covers a segment of key events, an executive summary, descriptive overview of Alzheimer's disease, explaining its causes, signs and symptoms, and currently available therapies.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
- Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
- A detailed review of the Alzheimer's disease market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Alzheimer's disease market.
Alzheimer's disease Report Insights
- Patient Population
- Therapeutic Approaches
- Alzheimer's Disease Pipeline Analysis
- Alzheimer's Disease Market Size and Trends
- Existing and Future Market Opportunity
Alzheimer's Disease Report Key Strengths
- 11 years Forecast
- The 7MM Coverage
- Alzheimer's Disease Epidemiology Segmentation
- Key Cross Competition
- Conjoint Analysis
- Drugs Uptake and Key Market Forecast Assumptions
Alzheimer's Disease Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
Key Questions:
Market Insights
- What was the Alzheimer's Disease market share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Alzheimer's Disease total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Alzheimer's Disease market size during the forecast period (2024-2034)?
- At what CAGR, the Alzheimer's Disease market is expected to grow at the 7MM level during the forecast period (2024-2034)?
- What would be the Alzheimer's Disease market outlook across the 7MM during the forecast period (2024-2034)?
- What would be the Alzheimer's Disease market growth till 2034 and what will be the resultant market size in the year 2034?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights
- What is the disease risk, burden, and unmet needs of Alzheimer's Disease?
- What is the historical Alzheimer's Disease patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient population of Alzheimer's disease at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Alzheimer's Disease?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Alzheimer's Disease during the forecast period (2024-2034)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2024-2034)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current options for the treatment of Alzheimer's Disease along with the approved therapy?
- What are the current treatment guidelines for the treatment of Alzheimer's Disease in the US, Europe, And Japan?
- What are the Alzheimer's Disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Alzheimer's Disease?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Alzheimer's Disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Alzheimer's Disease therapies?
- What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alzheimer's Disease and their status?
- What are the key designations that have been granted for the emerging therapies for Alzheimer's Disease?
- What are the 7MM historical and forecasted market of Alzheimer's Disease?
Reasons to Buy:
- The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Alzheimer's Disease Market.
- Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Detailed analysis and potential of current and emerging therapies under the conjoint analysis section to provide visibility around leading emerging drugs.
- Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
- To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future.
- Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.
Frequently Asked Questions:
1. What is the forecast period covered in the report?
The Alzheimer's Disease Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.
2. Who are the key players in the Alzheimer's Disease market?
The Alzheimer's Disease market is quite robust. The major layers are Alzheon Inc., Cerecin, BioVie Inc, AbbVie, and others which are currently developing drugs for the treatment of Alzheimer's disease.
3. How is the market size estimated in the forecast report?
The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as prevalent cases, treatment costs, revenue generated, and market trends.
4. What is the key driver of the Alzheimer's Disease market?
The increase in diagnosed prevalent cases of Alzheimer's Disease and the launch of emerging therapies are attributed to be the key drivers for increasing the Alzheimer's disease market.
5. What is the expected impact of emerging therapies or advancements in Alzheimer's Disease treatment on the market?
Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Alzheimer's disease treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.
6. Does the report provide insights into the competitive landscape of the market?
The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Alzheimer's Disease market.
Table of Contents
1. Key Insights
2. Report Introduction
3. Alzheimer's disease Market Overview at a Glance
- 3.1. Market Share (%) Distribution of Alzheimer's disease in 2020
- 3.2. Market Share (%) Distribution of Alzheimer's disease in 2034
4. Methodology of Alzheimer's disease Epidemiology and Market
5. Executive Summary of Alzheimer's Disease
6. Key Events
7. Disease Background and Overview
- 7.1. Introduction to Alzheimer's Disease
- 7.2. Signs and Symptoms
- 7.3. Classification of Alzheimer's Disease
- 7.4. Risk Factors
- 7.5. Severity of Alzheimer's Disease
- 7.6. Pathophysiology
- 7.6.1. Neurofibrillary Tangle Formation
- 7.6.2. Cholinergic Neurotransmitter System Dysfunctioning
- 7.6.3. Amyloid Beta (AB) Accumulation
- 7.6.4. Mitochondrial Dysfunction
- 7.6.5. Inflammation
- 7.6.5.1. Neuroinflammation in Alzheimer's disease
- 7.7. Diagnosis
- 7.7.1. Diagnostic Algorithm
- 7.7.2. National Institute on Aging and the Alzheimer's Association Criteria
- 7.7.3. DSM-5 Criteria for Diagnosing Alzheimer's disease
- 7.7.4. IWG-2 Criteria for Alzheimer's disease
- 7.7.5. Techniques
- 7.7.6. Mini-Mental State Exam (MMSE)
- 7.8. Treatment
- 7.8.1. Psychosocial Approach
- 7.8.2. Caregiving
- 7.8.3. Diet
- 7.8.4. Treatment Algorithms
- 7.8.5. Treatment Guidelines
- 7.8.5.1. Italian Association of Psychogeriatric Guidelines for Alzheimer's disease
- 7.8.5.2. National Institute for Health and Care Excellence (NICE) Guidelines for Alzheimer's disease
- 7.8.5.3. European Federation of the Neurological Societies (EFNS) Guidelines for the Diagnosis and Management of Alzheimer's disease
- 7.8.5.4. American Psychiatric Association (APA) Guidelines for Alzheimer's disease
- 7.8.5.5. Japanese Clinical Practice Guideline for Alzheimer's Disease Dementia 2017
8. Patient Journey
9. Epidemiology and Patient Population
- 9.1. Key Findings
- 9.2. Assumptions and Rationale: The 7MM
- 9.2.1. Diagnosed Prevalent Cases of Alzheimer's Disease
- 9.2.2. Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease
- 9.2.3. Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease
- 9.2.4. Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease
- 9.2.5. Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease
- 9.2.6. Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease
- 9.3. Total Diagnosed Prevalent Cases of Alzheimer's Disease in the 7MM
- 9.4. The US
- 9.4.1. Total Diagnosed Prevalent Cases of Alzheimer's Disease in the US
- 9.4.2. Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the US
- 9.4.3. Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the US
- 9.4.4. Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the US
- 9.4.5. Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the US
- 9.4.6. Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in the US
- 9.5. EU4 and the UK
- 9.5.1. Germany
- 9.5.1.1. Total Diagnosed Prevalent Cases of Alzheimer's Disease in Germany
- 9.5.1.2. Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Germany
- 9.5.1.3. Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Germany
- 9.5.1.4. Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Germany
- 9.5.1.5. Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in Germany
- 9.5.1.6. Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in Germany
- 9.5.2. France
- 9.5.2.1. Total Diagnosed Prevalent Cases of Alzheimer's Disease in France
- 9.5.2.2. Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in France
- 9.5.2.3. Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in France
- 9.5.2.4. Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in France
- 9.5.2.5. Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in France
- 9.5.2.6. Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in France
- 9.5.3. Italy
- 9.5.3.1. Total Diagnosed Prevalent Cases of Alzheimer's Disease in Italy
- 9.5.3.2. Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Italy
- 9.5.3.3. Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Italy
- 9.5.3.4. Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Italy
- 9.5.3.5. Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in Italy
- 9.5.3.6. Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in Italy
- 9.5.4. Spain
- 9.5.4.1. Total Diagnosed Prevalent Cases of Alzheimer's Disease in Spain
- 9.5.4.2. Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Spain
- 9.5.4.3. Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Spain
- 9.5.4.4. Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Spain
- 9.5.4.5. Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in Spain
- 9.5.4.6. Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in Spain
- 9.5.5. The United Kingdom
- 9.5.5.1. Total Diagnosed Prevalent Cases of Alzheimer's Disease in the UK
- 9.5.5.2. Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the UK
- 9.5.5.3. Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the UK
- 9.5.5.4. Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the UK
- 9.5.5.5. Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the UK
- 9.5.5.6. Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in the UK
- 9.5.1. Germany
- 9.6. Japan
- 9.6.1. Total Diagnosed Prevalent Cases of Alzheimer's Disease in Japan
- 9.6.2. Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Japan
- 9.6.3. Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Japan
- 9.6.4. Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Japan
- 9.6.5. Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in Japan
- 9.6.6. Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in Japan
10. Marketed Drugs
- 10.1. Key Cross Competition of Marketed Drugs
- 10.2. LEQEMBI (lecanemab): Biogen Inc./Eisai Co., Ltd.
- 10.2.1. Product Description
- 10.2.2. Regulatory Milestones
- 10.2.3. Other Developmental Activities
- 10.2.4. Clinical Trials Information
- 10.2.5. Safety and Efficacy
- 10.3. KISUNLA (Donanemab): Eli Lilly and Company
- 10.3.1. Product Description
- 10.3.2. Regulatory Milestones
- 10.3.3. Other Developmental Activities
- 10.3.4. Clinical Trials Information
- 10.3.5. Safety and Efficacy
- 10.4. REXULTI (brexpiprazole): Otsuka Pharmaceutical Co., Ltd./Lundbeck LLC
- 10.4.1. Product Description
- 10.4.2. Regulatory Milestones
- 10.4.3. Other Developmental Activities
- 10.4.4. Clinical Trials Information
- 10.4.5. Safety and Efficacy
11. Emerging Drug Profiles
- 11.1. Key Cross Competition
- 11.2. Masitinib (AB1010): AB Science
- 11.2.1. Product Description
- 11.2.2. Other Developmental Activities
- 11.2.3. Clinical Trials Information
- 11.2.4. Safety and Efficacy
- 11.2.5. Analyst Views
- 11.3. Valiltramiprosate (ALZ-801): Alzheon Inc.
- 11.3.1. Product Description
- 11.3.2. Other Developmental Activities
- 11.3.3. Clinical Trials Information
- 11.3.4. Safety and Efficacy
- 11.3.5. Analyst Views
- 11.4. Mirodenafil (AR1001): AriBio Co., Ltd.
- 11.4.1. Product Description
- 11.4.2. Other Developmental Activities
- 11.4.3. Clinical Trials Information
- 11.4.4. Safety and Efficacy
- 11.4.5. Analyst Views
- 11.5. Levetiracetam (AGB101): AgeneBio, Inc.
- 11.5.1. Product Description
- 11.5.2. Other Developmental Activities
- 11.5.3. Clinical Trials Information
- 11.5.4. Safety and Efficacy
- 11.5.5. Analyst Views
- 11.6. Blarcamesine (ANAVEX2-73): Anavex Life Sciences Corp.
- 11.6.1. Product Description
- 11.6.2. Other Developmental Activities
- 11.6.3. Clinical Trials Information
- 11.6.4. Safety and Efficacy
- 11.6.5. Analyst Views
- 11.7. Buntanetap (ANVS401 or posiphen): Annovis Bio, Inc.
- 11.7.1. Product Description
- 11.7.2. Other Developmental Activities
- 11.7.3. Clinical Trials Information
- 11.7.4. Safety and Efficacy
- 11.7.5. Analyst Views
- 11.8. Tricaprilin (CER0001): Cerecin
- 11.8.1. Product Description
- 11.8.2. Other Developmental Activities
- 11.8.3. Clinical Trials Information
- 11.8.4. Safety and Efficacy
- 11.8.5. Analyst Views
- 11.9. Bezisterim (NE3107): BioVie
- 11.9.1. Product Description
- 11.9.2. Other Developmental Activities
- 11.9.3. Clinical Trials Information
- 11.9.4. Safety and Efficacy
- 11.9.5. Analyst Views
- 11.1. Simufilam (PTI-125): Cassava Sciences
- 11.10.1. Product Description
- 11.10.2. Other Developmental Activities
- 11.10.3. Clinical Trials Information
- 11.10.4. Safety and Efficacy
- 11.10.5. Analyst Views
- 11.11. Semaglutide (NN6535): Novo Nordisk
- 11.11.1. Product Description
- 11.11.2. Clinical Trial Information
- 11.11.3. Safety and Efficacy
- 11.11.4. Analyst Views
- 11.12. Remternetug (LY3372993): Eli Lilly
- 11.12.1. Product Description
- 11.12.2. Clinical Trial Information
- 11.12.3. Safety and Efficacy
- 11.12.4. Analyst Views
- 11.13. Piromelatine (Neu-P11): Neurim Pharmaceuticals
- 11.13.1. Product Description
- 11.13.2. Clinical Trials Information
- 11.13.3. Safety and Efficacy
- 11.13.4. Analyst Views
- 11.14. Masupirdine (SUVN-502): Suven Life Sciences
- 11.14.1. Product Description
- 11.14.2. Other Development Activities
- 11.14.3. Clinical Trial Information
- 11.14.4. Safety and Efficacy
- 11.14.5. Analyst Views
- 11.15. KarXT (Trospium Chloride/Xanomeline): Bristol Myeris Squibb/Karuna Therapeutics
- 11.15.1. Product Description
- 11.15.2. Other Development Activities
- 11.15.3. Clinical Trial Information
- 11.15.4. Analyst Views
- 11.16. T3D-959: T3D Therapeutics, Inc.
- 11.16.1. Product Description
- 11.16.2. Other Development Activities
- 11.16.3. Clinical Trials Information
- 11.16.4. Safety and Efficacy
- 11.16.5. Analyst Views
- 11.17. LX 1001: Lexeo Therapeutics
- 11.17.1. Product Description
- 11.17.2. Other Development Activities
- 11.17.3. Clinical Trials Information
- 11.17.4. Safety and Efficacy
- 11.17.5. Analyst Views
- 11.18. AXS-05 (Bupropion/Dextromethorphan): Axsome Therapeutics, Inc.
- 11.18.1. Product Description
- 11.18.2. Other Development Activities
- 11.18.3. Clinical Trials Information
- 11.18.4. Safety and Efficacy
- 11.18.5. Analyst Views
- 11.19. ABvac40: Araclon Biotech S.L.
- 11.19.1. Product Description
- 11.19.2. Other Development Activities
- 11.19.3. Clinical Trials Information
- 11.19.4. Safety and Efficacy
- 11.19.5. Analyst Views
- 11.2. E2814: Eisai Co., Ltd.
- 11.20.1. Product Description
- 11.20.2. Other Developmental Activity
- 11.20.3. Clinical Trials Information
- 11.20.4. Safety and Efficacy
- 11.20.5. Analysts' Views
- 11.21. Hydromethylthionine Mesylate (HMTM)/TRx0237: TauRx Therapeutics
- 11.21.1. Product Description
- 11.21.2. Other Developmental Activity
- 11.21.3. Clinical Trials Information
- 11.21.4. Safety and Efficacy
- 11.21.5. Analyst's Views
- 11.22. TB006: TrueBinding, Inc.
- 11.22.1. Product Description
- 11.22.2. Other Developmental Activity
- 11.22.3. Clinical Trials Information
- 11.22.4. Safety and Efficacy
- 11.22.5. Analysts' Views
- 11.23. ACI-35.030/JNJ-2056 : AC Immune SA/Johnson & Johnson
- 11.23.1. Product Description
- 11.23.2. Other Developmental Activities
- 11.23.3. Clinical Trials Information
- 11.23.4. Safety and Efficacy
- 11.23.5. Analysts' Views
- 11.24. Allogeneic MSC/Lomecel-B: Longeveron Inc.
- 11.24.1. Product Description
- 11.24.1. Other Developmental Activities
- 11.24.2. Clinical Trials Information
- 11.24.3. Safety and Efficacy
- 11.24.4. Analysts' Views
- 11.25. Pepinemab: Vaccinex Inc.
- 11.25.1. Product Description
- 11.25.2. Clinical Trials Information
- 11.25.3. Safety and Efficacy
- 11.25.4. Analysts' Views
- 11.26. IGC-AD1 : IGC Pharma LLC
- 11.26.1. Product Description
- 11.26.2. Clinical Trials Information
- 11.26.3. Safety and Efficacy
- 11.26.4. Analysts' Views
12. Alzheimer's disease: Market Analysis
- 12.1. Key Findings
- 12.2. Key Market Forecast Assumptions
- 12.3. Market Outlook
- 12.4. Conjoint Analysis
- 12.5. Total Market Size of Alzheimer's disease in the 7MM
- 12.6. Market Size of Alzheimer's Disease by Therapies in the 7MM
- 12.7. Market Size of Alzheimer's disease in the US
- 12.7.1. Total Market Size of Alzheimer's disease in the US
- 12.7.2. Market Size of Alzheimer's Disease by Therapies in the United States
- 12.8. Market Size of Alzheimer's disease in EU4 and the UK
- 12.8.1. Market Size of Alzheimer's disease in Germany
- 12.8.1.1. Total Market Size of Alzheimer's disease in Germany
- 12.8.1.2. Market Size of Alzheimer's Disease by Therapies in Germany
- 12.8.2. Market Size of Alzheimer's disease in France
- 12.8.2.1. Total Market Size of Alzheimer's disease in France
- 12.8.2.2. Market Size of Alzheimer's Disease by Therapies in France
- 12.8.3. Market Size of Alzheimer's disease in Italy
- 12.8.3.1. Total Market Size of Alzheimer's disease in Italy
- 12.8.3.2. Market Size of Alzheimer's Disease by Therapies in Italy
- 12.8.4. Market Size of Alzheimer's disease in Spain
- 12.8.4.1. Total Market Size of Alzheimer's disease in Spain
- 12.8.4.2. Market Size of Alzheimer's Disease by Therapies in Spain
- 12.8.5. Market Size of Alzheimer's disease in the UK
- 12.8.5.1. Total Market Size of Alzheimer's disease in the UK
- 12.8.5.2. Market Size of Alzheimer's Disease by Therapies in the UK
- 12.8.1. Market Size of Alzheimer's disease in Germany
- 12.9. Market Size of Alzheimer's disease in Japan
- 12.9.1. Total Market Size of Alzheimer's disease in Japan
- 12.9.2. Market Size of Alzheimer's Disease by Therapies in Japan
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
- 16.1. The United States
- 16.1.1. Center for Medicare and Medicaid Services (CMS)
- 16.2. In EU4 and the UK
- 16.2.1. Germany
- 16.2.2. France
- 16.2.3. Italy
- 16.2.4. Spain
- 16.2.5. The United Kingdom
- 16.3. Japan
- 16.3.1. MHLW
17. Appendix
- 17.1. Bibliography
- 17.2. Acronyms and Abbreviations
- 17.3. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
List of Tables
- Table 1: Summary of Market and Epidemiology (2020-2034)
- Table 2: Key Events for Alzheimer's Disease
- Table 3: DSM-5 Diagnostic Criteria for Diagnosing Alzheimer's disease
- Table 4: IWG-2 Criteria for Alzheimer's disease
- Table 5: Interpreting the Results Using MMSE Scoring Chart
- Table 6: Guidelines for the use of AChE Inhibitors and Other Pharmacotherapies in the Management of Alzheimer's disease
- Table 7: Guidelines for the use of Memantine in the Management of Alzheimer's disease
- Table 8: The NICE guideline for Alzheimer's disease
- Table 9: EFNS Guideline for Alzheimer's disease
- Table 10: APA Guideline for Alzheimer's disease
- Table 11: Japanese Clinical Practice Guideline for Alzheimer's Disease Dementia 2017
- Table 12: Total Diagnosed Prevalent Cases of Alzheimer's Disease in the 7MM, in the thousands (2020-2034)
- Table 13: Total Diagnosed Prevalent Cases of Alzheimer's Disease in the US, in thousands (2020-2034)
- Table 14: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the US, in thousands (2020-2034)
- Table 15: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the US, in thousands (2020-2034)
- Table 16: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the US, in thousands (2020-2034)
- Table 17: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the US, in thousands (2020-2034)
- Table 18: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in the US, in thousands (2020-2034)
- Table 19: Diagnosed Prevalent Cases of Alzheimer's Disease in EU4 and the UK, in thousands (2020-2034)
- Table 20: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in EU4 and the UK, in thousands (2020-2034)
- Table 21: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in EU4 and the UK, in thousands (2020-2034)
- Table 22: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in EU4 and the UK, in thousands (2020-2034)
- Table 23: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in EU4 and the UK, in thousands (2020-2034)
- Table 24: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in EU4 and the UK, in thousands (2020-2034)
- Table 25: Diagnosed Prevalent Cases of Alzheimer's Disease in Germany, in thousands (2020-2034)
- Table 26: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Germany, in thousands (2020-2034)
- Table 27: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Germany, in thousands (2020-2034)
- Table 28: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Germany, in thousands (2020-2034)
- Table 29: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in Germany, in thousands (2020-2034)
- Table 30: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in Germany, in thousands (2020-2034)
- Table 31: Diagnosed Prevalent Cases of Alzheimer's Disease in France, in thousands (2020-2034)
- Table 32: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in France, in thousands (2020-2034)
- Table 33: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in France, in thousands (2020-2034)
- Table 34: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in France, in thousands (2020-2034)
- Table 35: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in France, in thousands (2020-2034)
- Table 36: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in France, in thousands (2020-2034)
- Table 37: Diagnosed Prevalent Cases of Alzheimer's Disease in Italy, in thousands (2020-2034)
- Table 38: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Italy, in thousands (2020-2034)
- Table 39: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Italy, in thousands (2020-2034)
- Table 40: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Italy, in thousands (2020-2034)
- Table 41: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in Italy, in thousands (2020-2034)
- Table 42: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in Italy, in thousands (2020-2034)
- Table 43: Diagnosed Prevalent Cases of Alzheimer's Disease in Spain, in thousands (2020-2034)
- Table 44: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Spain, in thousands (2020-2034)
- Table 45: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Spain, in thousands (2020-2034)
- Table 46: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Spain, in thousands (2020-2034)
- Table 47: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in Spain, in thousands (2020-2034)
- Table 48: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in Spain, in thousands (2020-2034)
- Table 49: Diagnosed Prevalent Cases of Alzheimer's Disease in the UK, in thousands (2020-2034)
- Table 50: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the UK, in thousands (2020-2034)
- Table 51: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the UK, in thousands (2020-2034)
- Table 52: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the UK, in thousands (2020-2034)
- Table 53: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the UK, in thousands (2020-2034)
- Table 54: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in the UK, in thousands (2020-2034)
- Table 55: Diagnosed Prevalent Cases of Alzheimer's Disease in Japan, in thousands (2020-2034)
- Table 56: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Japan, in thousands (2020-2034)
- Table 57: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Japan, in thousands (2020-2034)
- Table 58: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Japan, in thousands (2020-2034)
- Table 59: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in Japan, in thousands (2020-2034)
- Table 60: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in Japan, in thousands (2020-2034)
- Table 61: Key Cross Competition of Marketed Drugs
- Table 62: LEQEMBI (lecanemab), Clinical Trial Description, 2024
- Table 63: KISUNLA (Donanemab), Clinical Trial Description, 2024
- Table 64: REXULTI (brexpiprazole), Clinical Trial Description, 2024
- Table 65: Comparison of Emerging Drugs
- Table 66: Masitinib, Clinical Trial Description, 2024
- Table 67: ALZ-801, Clinical Trial Description, 2024
- Table 68: AR1001, Clinical Trial Description, 2024
- Table 69: AGB101, Clinical Trial Description, 2024
- Table 70: Blarcamesine, Clinical Trial Description, 2024
- Table 71: ANVS401, Clinical Trial Description, 2024
- Table 72: Tricaprilin, Clinical Trial Description, 2024
- Table 73: Bezisterim (NE3107), Clinical Trial Description, 2024
- Table 74: Simufilam (PTI-125), Clinical Trial Description, 2024
- Table 75: Semaglutide (NN6535), Clinical Trial Description, 2024
- Table 76: Remternetug (LY3372993), Clinical Trial Description, 2024
- Table 77: Piromelatine (Neu-P11), Clinical Trial Description, 2024
- Table 78: Masupirdine (SUVN-502), Clinical Trial Description, 2024
- Table 79: KarXT (Trospium chloride/xanomeline), Clinical Trial Description, 2024
- Table 80: T3D-959, Clinical Trial Description, 2024
- Table 81: LX1001, Clinical Trial Description, 2024
- Table 82: AXS-05 (Bupropion/dextromethorphan), Clinical Trial Description, 2024
- Table 83: ABvac40, Clinical Trial Description, 2024
- Table 84: E2814, Clinical Trial Description, 2024
- Table 85: Hydromethylthionine mesylate (HMTM)/TRx0237 Clinical Trial Description, 2024
- Table 86: TB006, Clinical Trial Description, 2024
- Table 87: ACI-35.030, Clinical Trial Description, 2024
- Table 88: Allogeneic MSC, Clinical Trial Description, 2024
- Table 89: Pepinemab, Clinical Trial Description, 2024
- Table 90: IGC-AD1, Clinical Trial Description, 2024
- Table 91: Key Market Forecast Assumptions for NE3107
- Table 92: Key Market Forecast Assumptions for Masitinib (AB1010)
- Table 93: Key Market Forecast Assumptions for Simufilam (PTI-125)
- Table 94: Key Market Forecast Assumptions for Semaglutide (NN6535)
- Table 95: Key Market Forecast Assumptions for Remternetug (LY3372993)
- Table 96: Key Market Forecast Assumptions for AR1001
- Table 97: Key Market Forecast Assumptions for Piromelatine (Neu-P11)
- Table 98: Key Market Forecast Assumptions for Tricaprilin (CER-0001) (AC-1204)
- Table 99: Key Market Forecast Assumptions for Buntanetap
- Table 100: Key Market Forecast Assumptions for ANAVEX2-73 (blarcamesine)
- Table 101: Key Market Forecast Assumptions for E2814
- Table 102: Key Market Forecast Assumptions for AGB101-extended-release formulation of levetiracetam
- Table 103: Key Market Forecast Assumptions for Valiltramiprosate (ALZ-801)
- Table 104: Key Market Forecast Assumptions for Hydromethylthionine Mesylate (HMTM)
- Table 105: Key Market Forecast Assumptions for Bupropion/Dextromethorphan (AXS-05)
- Table 106: Key Market Forecast Assumptions for KarXT (Trospium Chloride/Xanomeline)
- Table 107: Key Market Forecast Assumptions for Masupirdine (SUVN-502)
- Table 108: Key Market Forecast Assumptions for Pepinemab
- Table 109: Key Market Forecast Assumptions for T3D-959
- Table 110: Key Market Forecast Assumptions for TB006
- Table 111: Key Market Forecast Assumptions for IGC-AD1
- Table 112: Key Market Forecast Assumptions for ABvac40
- Table 113: Key Market Forecast Assumptions for ACI-35.030
- Table 114: Key Market Forecast Assumptions for LX1001
- Table 115: Key Market Forecast Assumptions for Allogeneic MSCs/ Lomecel-B
- Table 116: Total Market Size of Alzheimer's disease in the 7MM, in USD million (2020-2034)
- Table 117: Market Size of Alzheimer's Disease by Therapies in the 7MM, USD million (2020-2034)
- Table 118: Total Market Size of Alzheimer's disease in the US, in USD million (2020-2034)
- Table 119: Market Size of Alzheimer's Disease by Therapies in the United States, USD million (2020-2034)
- Table 120: Total Market Size of Alzheimer's disease in EU4 and the UK, in USD million (2020-2034)
- Table 121: Market Size of Alzheimer's Disease by Therapies in EU4 and the UK, USD million (2020-2034)
- Table 122: Total Market Size of Alzheimer's disease in Germany, in USD million (2020-2034)
- Table 123: Market Size of Alzheimer's Disease by Therapies in Germany, USD million (2020-2034)
- Table 124: Total Market Size of Alzheimer's disease in France, in USD million (2020-2034)
- Table 125: Market Size of Alzheimer's Disease by Therapies in France, USD million (2020-2034)
- Table 126: Total Market Size of Alzheimer's disease in Italy, in USD million (2020-2034)
- Table 127: Market Size of Alzheimer's Disease by Therapies in Italy, USD million (2020-2034)
- Table 128: Total Market Size of Alzheimer's disease in Spain, in USD million (2020-2034)
- Table 129: Market Size of Alzheimer's Disease by Therapies in Spain, USD million (2020-2034)
- Table 130: Total Market Size of Alzheimer's disease in the UK, in USD million (2020-2034)
- Table 131: Market Size of Alzheimer's Disease by Therapies in the UK, USD million (2020-2034)
- Table 132: Total Market Size of Alzheimer's disease in Japan, in USD million (2020-2034)
- Table 133: Market Size of Alzheimer's Disease by Therapies in Japan, USD million (2020-2034)
List of Figures
- Figure 1: Symptoms of Alzheimer's disease
- Figure 2: Classification of Alzheimer's disease
- Figure 3: Risk Factors of Alzheimer's disease
- Figure 4: Risk Factors of Alzheimer's disease
- Figure 5: Stages of Alzheimer's disease
- Figure 6: Pathophysiology of Alzheimer's Disease
- Figure 7: Diagnostic Algorithm
- Figure 8: Treatment of Alzheimer's disease
- Figure 9: Flow Chart for Treating Alzheimer's disease
- Figure 10: Treatment Algorithm
- Figure 11: Treatment Algorithm of Alzheimer's disease
- Figure 12: Patient Journey
- Figure 13: Total Diagnosed Prevalent Cases of Alzheimer's Disease in the 7MM (2020-2034)
- Figure 14: Total Diagnosed Prevalent Cases of Alzheimer's Disease in the US (2020-2034)
- Figure 15: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the US (2020-2034)
- Figure 16: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the US (2020-2034)
- Figure 17: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the US (2020-2034)
- Figure 18: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the US (2020-2034)
- Figure 19: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in the US (2020-2034)
- Figure 20: Total Diagnosed Prevalent Cases of Alzheimer's Disease in EU4 and the UK (2020-2034)
- Figure 21: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in EU4 and the UK (2020-2034)
- Figure 22: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in EU4 and the UK (2020-2034)
- Figure 23: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in EU4 and the UK (2020-2034)
- Figure 24: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in EU4 and the UK (2020-2034)
- Figure 25: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in EU4 and the UK (2020-2034)
- Figure 26: Total Diagnosed Prevalent Cases of Alzheimer's Disease in Germany (2020-2034)
- Figure 27: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Germany (2020-2034)
- Figure 28: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Germany (2020-2034)
- Figure 29: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Germany (2020-2034)
- Figure 30: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in Germany (2020-2034)
- Figure 31: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in Germany (2020-2034)
- Figure 32: Total Diagnosed Prevalent Cases of Alzheimer's Disease in France (2020-2034)
- Figure 33: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in France (2020-2034)
- Figure 34: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in France (2020-2034)
- Figure 35: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in France (2020-2034)
- Figure 36: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in France (2020-2034)
- Figure 37: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in France (2020-2034)
- Figure 38: Total Diagnosed Prevalent Cases of Alzheimer's Disease in Italy (2020-2034)
- Figure 39: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Italy (2020-2034)
- Figure 40: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Italy (2020-2034)
- Figure 41: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Italy (2020-2034)
- Figure 42: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in Italy (2020-2034)
- Figure 43: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in Italy (2020-2034)
- Figure 44: Total Diagnosed Prevalent Cases of Alzheimer's Disease in Spain (2020-2034)
- Figure 45: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Spain (2020-2034)
- Figure 46: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Spain (2020-2034)
- Figure 47: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Spain (2020-2034)
- Figure 48: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in Spain (2020-2034)
- Figure 49: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in Spain (2020-2034)
- Figure 50: Total Diagnosed Prevalent Cases of Alzheimer's Disease in the UK (2020-2034)
- Figure 51: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the UK (2020-2034)
- Figure 52: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the UK (2020-2034)
- Figure 53: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in the UK (2020-2034)
- Figure 54: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in the UK (2020-2034)
- Figure 55: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in the UK (2020-2034)
- Figure 56: Total Diagnosed Prevalent Cases of Alzheimer's Disease in Japan (2020-2034)
- Figure 57: Gender-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Japan (2020-2034)
- Figure 58: Age-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Japan (2020-2034)
- Figure 59: Severity-specific Diagnosed Prevalent Cases of Alzheimer's Disease in Japan (2020-2034)
- Figure 60: Diagnosed Prevalent Cases of Agitation in Alzheimer's Disease in Japan (2020-2034)
- Figure 61: Diagnosed Prevalent Cases of Psychosis in Alzheimer's Disease in Japan (2020-2034)
- Figure 62: Total Market Size of Alzheimer's disease in the 7MM, in USD million (2020-2034)
- Figure 63: Market Size of Alzheimer's Disease by Therapies in the 7MM, USD million (2020-2034)
- Figure 64: Total Market Size of Alzheimer's disease in the US, in USD million (2020-2034)
- Figure 65: Market Size of Alzheimer's Disease by Therapies in the United States, USD million (2020-2034)
- Figure 66: Total Market Size of Alzheimer's disease in EU4 and the UK, in USD million (2020-2034)
- Figure 67: Market Size of Alzheimer's Disease by Therapies in EU4 and the UK, USD million (2020-2034)
- Figure 68: Total Market Size of Alzheimer's disease in Germany, in USD million (2020-2034)
- Figure 69: Market Size of Alzheimer's Disease by Therapies in Germany, USD million (2020-2034)
- Figure 70: Total Market Size of Alzheimer's disease in France, in USD million (2020-2034)
- Figure 71: Market Size of Alzheimer's Disease by Therapies in France, USD million (2020-2034)
- Figure 72: Total Market Size of Alzheimer's disease in Italy, in USD million (2020-2034)
- Figure 73: Market Size of Alzheimer's Disease by Therapies in Italy, USD million (2020-2034)
- Figure 74: Total Market Size of Alzheimer's disease in Spain, in USD million (2020-2034)
- Figure 75: Market Size of Alzheimer's Disease by Therapies in Spain, USD million (2020-2034)
- Figure 76: Total Market Size of Alzheimer's disease in the UK, in USD million (2020-2034)
- Figure 77: Market Size of Alzheimer's Disease by Therapies in the UK, USD million (2020-2034)
- Figure 78: Total Market Size of Alzheimer's disease in Japan, in USD million (2020-2034)
- Figure 79: Market Size of Alzheimer's Disease by Therapies in Japan, USD million (2020-2034)
- Figure 80: SWOT Analysis
- Figure 81: Unmet Needs
- Figure 82: Health Technology Assessment
- Figure 83: Reimbursement Process in the United States
- Figure 84: Reimbursement Process in Germany
- Figure 85: Reimbursement Process in France
- Figure 86: Reimbursement process in Italy
- Figure 87: Reimbursement Process in Spain
- Figure 88: Reimbursement Process in the United Kingdom
- Figure 89: Reimbursement Process in Japan
